Skip to main content
Midas Edge

Nurix Therapeutics, Inc.

For the period ended Aug 31, 2025. Filed Oct 9, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Aug 31, 2025 · Filed Oct 9, 2025

NRIX$15.88-1.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Statements of Stockholders’ Equity

(in thousands, except share amounts)

Common stock · Additionalpaid-incapital · Accumulatedothercomprehensiveincome (loss) · Accumulated deficit · Totalstockholders’equity
Shares · Amount
Balance as of November 30, 202348,718,552$49$746,299$(655)$(545,200)$200,493
Exercise of stock options75,362—355——355
Vesting of restricted stock units171,030—————
Vesting of early exercised stock options——21——21
Repurchase of unvested early exercised stock(1,548)—————
Issuance of common stock under employee stock purchase plan173,558—1,269——1,269
Stock-based compensation——7,823——7,823
Unrealized gain on available-for-sale marketable securities———305—305
Net loss————(41,518)(41,518)
Balance as of February 29, 202449,136,95449755,767(350)(586,718)168,748
Issuance of common stock and pre-funded warrants in connection with equity financing, net of issuance costs of $12,51811,916,66712188,720——188,732
Issuance of common stock in “at the market” financing, net of issuance costs of $1,6843,194,809348,466——48,469
Exercise of stock options24,108—216——216
Vesting of restricted stock units83,997—————
Vesting of early exercised stock options——12——12
Stock-based compensation——8,847——8,847
Unrealized gain on available-for-sale marketable securities———215—215
Net loss————(44,546)(44,546)
Balance as of May 31, 202464,356,535641,002,028(135)(631,264)370,693
Issuance of common stock in “at the market” financing, net of issuance costs of $9202,145,000241,978——41,980
Exercise of stock options281,29113,034——3,035
Vesting of restricted stock units197,777—————
Issuance of common stock under employee stock purchase plan102,920—863——863
Stock-based compensation——8,762——8,762
Unrealized gain on available-for-sale marketable securities———479—479
Net loss————(48,956)(48,956)
Balance as of August 31, 202467,083,523$67$1,056,665$344$(680,220)$376,856
Common stock · Additionalpaid-incapital · Accumulatedothercomprehensiveincome (loss) · Accumulateddeficit · Totalstockholders’equity
Shares · Amount
Balance as of November 30, 202475,870,718$76$1,265,536$150$(738,769)$526,993
Exercise of stock options37,428—221——221
Vesting of restricted stock units242,923—————
Issuance of common stock under employee stock purchase plan83,730—1,252——1,252
Stock-based compensation——8,726——8,726
Unrealized gain on available-for-sale marketable securities———76—76
Net loss————(56,351)(56,351)
Balance as of February 28, 202576,234,799761,275,735226(795,120)480,917
Exercise of stock options1,233—6——6
Vesting of restricted stock units197,632—————
Stock-based compensation——10,390——10,390
Unrealized loss on available-for-sale marketable securities———(246)—(246)
Net loss————(43,464)(43,464)
Balance as of May 31, 202576,433,664761,286,131(20)(838,584)447,603
Exercise of stock options18,8221177——178
Vesting of restricted stock units311,485—————
Issuance of common stock under employee stock purchase plan108,715—977——977
Stock-based compensation——9,776——9,776
Unrealized gain on available-for-sale marketable securities———139—139
Net loss————(86,421)(86,421)
Balance as of August 31, 202576,872,686$77$1,297,061$119$(925,005)$372,252
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.